Human granulocytic anaplasmosis discovered in the Estrie, Québec
Published by: The Public Health Agency of Canada
Issue: Volume 48-5, May 2022: Vector-Borne Infections–Part 1: Ticks & Mosquitoes
Date published: May 2022
Volume 48-5, May 2022: Vector-Borne Infections–Part 1: Ticks & Mosquitoes
Identification of an unusual cluster of human granulocytic anaplasmosis in the Estrie region, Québec, Canada in 2021
Laurence Campeau1, Valérie Roy2, Geneviève Petit3,4, Geneviève Baron3,4, Jacinthe Blouin4, Alex Carignan2
1 Canadian Field Epidemiology Program, Public Health Agency of Canada, Ottawa, ON
2 Department of Microbiology and Infectious Diseases, Université de Sherbrooke, Sherbrooke, QC
3 Direction de la santé publique de l'Estrie (Estrie Public Health Department), Sherbrooke, QC
4 Department of Community Health Sciences, Université de Sherbrooke, Sherbrooke, QC
Campeau L, Roy V, Petit G, Baron G, Blouin J, Carignan A. Identification of an unusual cluster of human granulocytic anaplasmosis in the Estrie region, Québec, Canada in 2021. Can Commun Dis Rep 2022;48(5):188–95. https://doi.org/10.14745/ccdr.v48i05a02
Keywords: Anaplasma phagocytophilum, human granulocytic anaplasmosis, tick-borne disease, zoonosis
Background: Human granulocytic anaplasmosis (HGA) is a potentially severe tick-borne infection caused by the bacterium Anaplasma phagocytophilum (A. phagocytophilum) of the genus Rickettsia. Here, we describe the epidemiological and clinical characteristics of an unusual cluster of HGA cases detected in the Estrie region in Québec, Canada, during the 2021 transmission season.
Methods: Confirmed cases of HGA were defined as individuals with typical clinical manifestations and a positive polymerase chain reaction assay. The cases were interviewed using a structured questionnaire and clinical data was obtained from medical records.
Results: A total of 25 confirmed cases were identified during the 2021 transmission season, thus constituting the largest known cluster of HGA in Canada. The most common symptoms reported were fever, fatigue and headaches. Laboratory investigations found that 20 (80%) of the patients had thrombocytopenia and 18 (72%) had leukopenia at presentation. Almost half of the patients required hospitalization (n=11, 44%), with a median duration of four days (interquartile range [IQR] 2.5–5 days), including one patient who required intensive care. No deaths were recorded during the study. Epidemiological investigation found that all cases were domestically acquired, and yard maintenance was the most prevalent at-risk activity identified. Only seven (28%) cases had been aware of a tick bite in the previous two weeks.
Conclusion: Detection of this unusual cluster of HGA cases provides further evidence that A. phagocytophilum may now be established along the southern border of Québec. Clinicians should consider HGA when assessing patients with typical symptoms and recent exposure to high-risk environments for tick bite.
Human granulocytic anaplasmosis (HGA) is a tick-borne infection caused by the bacterium Anaplasma phagocytophilum (A. phagocytophilum) of the genus Rickettsia. In Northeastern America, the main vector of the disease is Ixodes scapularisFootnote 1, commonly known as the blacklegged tick, that also transmits Borrelia burgdorferi, the causative agent for Lyme disease (LD). Individuals usually develop nonspecific symptoms such as fever, chills, myalgias, malaise, severe headaches and gastrointestinal symptoms one to two weeks after exposureFootnote 2. While the illness can be severe and possibly life threatening if left untreated, antimicrobial treatment generally leads to resolution of symptoms within 48 hoursFootnote 3.
Human granulocytic anaplasmosis is primarily endemic in the upper Midwestern and Northeastern United StatesFootnote 4, but A. phagocytophilum has been detected in tick populations of all Canadian provinces in recent years. Nonetheless, data on HGA infections among humans in the Canadian context are limited because Manitoba and Québec are the only provinces where HGA is a reportable disease. Between 2015 and 2019, 37 confirmed cases were reported in ManitobaFootnote 5. In Québec, three confirmed cases have been reported to public health since the disease became subject to mandatory reporting for laboratories in 2019. This included one case in the Estrie region, which is located along the southern border of eastern Québec (personal communication, Institut national de santé publique du Québec [INSPQ]). Here, we describe the epidemiological and clinical characteristics of an unusual cluster of HGA infections reported in the Estrie region during the 2021 transmission season.
Study setting, population, and design
We conducted a retrospective case series analysis in the Estrie region, Québec, Canada that has a total population of 489,479Footnote 6. This region accounts for the majority of LD cases in the province and shares its southern border with three of the eight states in the United States with the highest incidence of HGA: Vermont; New Hampshire; and MaineFootnote 4. Our study sample included all confirmed cases of anaplasmosis in this region from May 1, 2021, to November 20, 2021. A confirmed HGA case was defined as an individual with typical clinical manifestations and a positive polymerase chain reaction (PCR) assayFootnote 7. As anaplasmosis is a notifiable disease in Québec, the list of patients with positive PCR results was extracted from the regional notifiable diseases database of the Direction de la santé publique de l'Estrie.
Laboratory methods for detection of tick-borne infections
All the diagnostic and confirmatory microbiological tests for Anaplasma phagocytophilum and other potential coinfections were performed either at the National Microbiology Laboratory in Winnipeg, Manitoba, at the Laboratoire de santé publique du Québec in Sainte-Anne de Bellevue, Québec, or at the National Reference Center for Parasitology in Montréal, Québec. Detailed laboratory testing methods are available in Annex.
One infectious disease fellow and one field epidemiologist in collaboration with the Communicable Disease team at the Direction de la santé publique de l'Estrie, performed chart reviews in three different acute care hospitals within the Centre intégré universitaire de santé et service sociaux de l'Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie – CHUS), where the confirmed cases were evaluated and treated. A standardized data abstraction form, which was developed by our research team after an initial literature review and pre-tested on one patient, was used for data collection. Past medical history was collected to calculate the Charlson Comorbidity IndexFootnote 8, along with demographic, microbiological, and treatment data. Data on symptoms, clinical signs, and laboratory findings were also collected. A standardized questionnaire to assess history of tick bite and possible exposure sources, including the location, the activities undertaken and their frequency, was built and all patients underwent a phone interview. Activities undertaken by the cases in the two weeks prior to symptom onset were considered at-risk if they took place in an area known to be endemic for LD and the environment was suitable for ticks (e.g. grassy, brushy or wooded areas). If a case practiced multiple at-risk activities during the time period, all activities were included in the descriptive analysis.
Geographic information and data visualization
Spatial data was uploaded to a geographic information software (QGIS 3.10.9) to develop a map of the location of residence of cases.
Data cleaning and descriptive analyses were performed using Excel 2016 and Stata version 15.1 (StataCorp, College Station, Texas, United States).
The Comité d'éthique clinique et organisationnelle (institutional review board) of the CIUSSS de l'Estrie-CHUS approved this study (Project #2022-4465).
During the study period, 25 confirmed cases were identified in the Estrie region (Figure 1). The patients' demographic and clinical characteristics are summarized in Table 1. The majority of cases were male (n=15, 60%) and the median age was 65 years. All cases were either permanent or seasonal residents of the regions of La Pommeraie or Haute-Yamaska at the time of exposure, with a majority of cases residing in the town of Bromont (n=16, 64%). None of the cases reported out-of-province travel in the previous two months. The activity most often reported by cases was yard maintenance (n=22, 88%), which included gardening, lawn mowing and wood chopping. Additionally, 48% (n=12) of the cases reported outdoor recreational activities such as walking, mountain biking and shooting practice, whereas five (20%) cases reported potential exposure while taking care of farm animals or visiting a farm. Overall, 28% (n=7) of the cases had observed a tick attached to their skin in the two weeks prior to symptom onset.
|Years, median (IQR)||65||53–70|
|Municipality of residence|
|At-risk activities reportedTable 1 Footnote a|
|Outdoor recreational activity||12||48|
|Farm visit or animal care||5||20|
|Recent out-of-province travel||0||0|
|Tick bite ≤2 weeks preceding symptom onset||7||28|
|Charlson comorbidity index|
|Symptoms and clinical signs|
|FeverTable 1 Footnote b||25||100|
|Duration of fever in days (median [IQR])Table 1 Footnote c||4||2–5|
|Duration of hospitalization in days (median [IQR])||4||2.5–5|
|Intensive care unit||1||4|
|ImmunosuppressionTable 1 Footnote d||3||12|
Most patients developed symptoms in either June (n=9) or July (n=11) (Figure 2). All cases experienced fever and reported symptoms such as fatigue (n=24; 96%), headaches (n=22; 88%), myalgia (n=20; 80%) and sweating (n=17; 68%). A significant proportion of patients presented gastrointestinal symptoms such as vomiting (n=11; 44%), diarrhea (n=9; 36%) and abdominal pain (n=8; 32%). Two cases (8%) reported a rash; in both cases the rashes were less than 5 cm in diameter and, therefore, not characteristic of erythema migrans. The detailed hematologic and biochemical laboratory findings are listed in Table 2. The most frequent laboratory anomalies were leukopenia (n=18/25; 72%), thrombocytopenia (n=20/25; 80%) and mildly elevated alanine aminotransferase levels (n=14/24; 58%).
|Hematologic and biochemical findings||n=25|
|Count upon presentation||3.3||2.5–5.2|
|Count upon presentation||2.4||1.4–3.9|
|Count upon presentation||0.7||0.2–1.0|
|Count upon presentation||114||72–141|
|AnemiaTable 2 Footnote a (n, [%])||9||36%|
|Alanine aminotransferase (IU/L)|
|C-reactive protein (mg/L)|
|Acute kidney injuryTable 2 Footnote b||3||12%|
Almost half of the patients required hospitalization (n=11; 44%), with a median duration of 4 days (interquartile range [IQR] 2.5–5 days), including one patient who required intensive care. Hospitalized patients were slightly older than those who did not require hospitalization, but this difference was not statistically significant (67.0 vs 61.3 years old; p=0.2). None of the patients died during the study period. All patients were treated with doxycycline for a median duration of 14 days (IQR 14–16 days).
The findings of the diagnostic tests for anaplasmosis and other potential coinfections are listed in Table 3. Anaplasma phagocytophilum serology (indirect immunofluorescence assay) was performed for 21 patients during the acute phase of infection and antibodies were detected in four patients. Convalescent-phase repeated testing was performed in two patients; none showed a four-fold increase in antibody titers. Interestingly, among patients with positive serology (n=4), the time between the start of symptoms and serology was significantly longer compared to patients with negative serology (median of 18.5 days vs 4.0 days), and an indeterminate serology result was obtained in a patient whose blood was drawn seven days after symptom onset. Three patients had peripheral smears showing morulae in the neutrophils in addition to positive PCR results. For other coinfections, 11 patients out of 23 tested positive using enzyme immunoassay (EIA) for Lyme serology, of whom seven were positive for isolated line blot IgM in the confirmatory test. The other four patients were positive for Lyme western blot IgG.
|Pathogen||Diagnostic test (positive results/total tests performed)|
|Polymerase chain reaction||Serology||Blood smear|
|Anaplasma phagocytophilum||25/25||4/21Table 3 Footnote a||3/4Table 3 Footnote b|
EIA: 11/23Table 3 Footnote c
Western blot IgG: 4/11
Line blot IgMTable 3 Footnote d: 7/7
This report describes the epidemiological and clinical features of a cluster of HGA cases in the Estrie region, located along the southern border of Québec. A total of 25 cases have been confirmed in 2021, thus constituting the largest reported cluster of confirmed HGA cases identified during a transmission season in Canada. Since the first reported case of HGA in Canada in 2009Footnote 9, surveillance data shows that HGA seroprevalence has increased among the populations of Manitoba and OntarioFootnote 10Footnote 11. Nonetheless, an article describing three cases in Manitoba is the only other publicly available case series that describes a cluster of confirmed HGA cases in CanadaFootnote 10.
Our data also provides further evidence that A. phagocytophilum may now be established in blacklegged tick populations in the Estrie region, as previously indicated by acarological surveillance programsFootnote 12. These findings are also consistent with a recent study that suggests an expansion of the suitable geographic areas for tick reservoirs and hosts, such as mice and deer, resulting in the emergence of tick-borne diseases in new areasFootnote 13. Before 2021, only three confirmed cases of human anaplasmosis had been reported to public health in Québec, including one in the Estrie regionFootnote 14.
In this study, most cases were observed in males, which is consistent with previous findings indicating that men are more likely to adopt behaviors that put them at risk of tick bitesFootnote 15Footnote 16. Only four patients were younger than 50 years old; however, this could be partly due to an increased likelihood of asymptomatic infections among younger individuals. Yard maintenance was the most common at-risk activity reported by cases during their exposure period. This is consistent with similar finding by Porter et al., which found that yard work was the most common activity practiced during tick encounters in a sample of individuals who submitted ticks through a passive tick surveillance system in the Northeastern United StatesFootnote 17.
Most cases had nonspecific symptoms such as fever, headaches and fatigue. Digestive symptoms were also prevalent in our case series. Laboratory abnormalities, including leukopenia, thrombocytopenia and elevated hepatic transaminase levels, were present in majority of patients. These data are consistent with the clinical and paraclinical presentations reported recentlyFootnote 1Footnote 18. The proportion of hospitalized patients seen in our sample was marginally higher than that reported in the national surveillance data in the United States from 2008 to 2012 (44% vs 31%)Footnote 3; however, the higher hospitalization rates were probably because HGA is not yet a well-recognized disease in our region and physicians may be less likely to identify HGA in outpatient settings.
It has been reported that among patients with positive Anaplasma phagocytophilum serology, 4%–36% show positive serology for either Borrelia burgdorferi or Babesia microtiFootnote 1. Interestingly, almost half of our patients had positive Lyme serology, but only two reported a nonspecific rash, which is not indicative of classic erythema migrans. Among those with positive EIA (n=11), four were positive for IgG (determined by western blot); this methodology was in line with the two-tier testing approach currently used in Canada. For those with positive EIA and negative IgG, IgM positivity was shown in all (using the line blot method). Although IgM titers are classically known to indicate a recent infection, there are limitations to the test. IgM can be falsely positive and can remain positive for months or years after the initial infectionFootnote 1. Therefore, even if a high proportion of the patients in our case series were IgM positive, it is difficult to conclude that all patients had a coinfection, especially without the manifestation of erythema migrans. Convalescent serology would have helped the confirmation of early coinfection with LD if IgG developed afterward, but these results were not available at the time of manuscript submission. No coinfection with Babesia microti was diagnosed in our series; this was expected since this parasite is not commonly found in ticks in the region according to acarological surveillance programsFootnote 12.
While HGA is a nationally reportable condition in the United StatesFootnote 19, it is only reported in the provinces of Manitoba and Québec in Canada. As suggested elsewhereFootnote 2Footnote 20, a nationally reportable disease status would improve epidemiologic monitoring, which is especially important in identifying other newly endemic areas. Mandatory reporting would also increase physician awareness of this emerging infection, facilitating early diagnosis and treatment. Early antimicrobial treatment of HGA is critical as it reduces the risk of severe complications and may be lifesaving for individuals at higher risk of death, such as immunocompromised and elderly patientsFootnote 10. The adoption of multiplex tests for tick-borne diseases should also be considered to facilitate the identification of emerging pathogens in areas where LD is already endemicFootnote 21.
Improvements to current acarological surveillance strategies are also needed to preemptively identify regions where A. phagocytophilum is most likely to occur. This was highlighted in the conclusions of the federal framework on LD in CanadaFootnote 14, which identified the development of a national tick-borne diseases surveillance system as a priority action item. This system would incorporate region-specific data on the distribution of vectors and the prevalence of disease-causing pathogens to improve the monitoring of the distribution of ticks capable of transmitting LD, HGA and other infections.
Furthermore, the primary prevention method for tick-borne diseases, including HGA, remains the adoption of preventive behaviors that reduce the risk of tick encounters. Existing LD health promotion efforts should be reinforced and, in regions where A. phagocytophilum has been detected, tailored to incorporate HGA. A multi-sectoral and multidisciplinary approach that involves both human and animal health stakeholders should also be emphasized to help identify prevention strategies that leverage the One Health approach, as well as to better understand the role of tick vectors, such as deer and mice, in the emergence of new risk areas for HGAFootnote 22.
Limitations of the study
Our study was limited by its observational design, as it included only cases reported to the public health department. Even if our definition of confirmed cases was based on a very specific and reliable assay (PCR), our data certainly underestimated the true burden of HGA in the region. Subclinical cases are likely to remain undetected and since this disease has only recently emerged in the area, physicians are likely to miss diagnoses due to lack of awareness. Another limitation of our study is that it was not possible to attribute the acquisition of HGA to a specific at-risk activity when multiple exposures took place in the two weeks prior to symptom onset; therefore, all activities were listed.
Human granulocytic anaplasmosis is a growing public health concern in the southern regions of Québec, Canada. A reportable disease status should be considered by provincial and federal jurisdictions, and health promotion efforts that aim to reduce the risk of tick encounters should be reinforced. Clinicians should consider the possibility of HGA when assessing patients with fever, leukopenia, thrombocytopenia, elevated hepatic transaminase levels and recent exposure to high-risk environments for tick bites. The initiation of empiric treatment with doxycycline should be considered prior to reception of PCR testing results when those results cannot be obtained in a timely manner.
LC — Collected the data, analyzed the data, interpreted the results, drafted the manuscript
VR — Collected the data, analyzed the data, interpreted the results, drafted the manuscript
AC — Analyzed the data, interpreted the results, drafted the manuscript
GP — Drafted the manuscript
GB — Drafted the manuscript
JB — Drafted the manuscript
All authors participated in designing the study methodology. All authors reviewed the results and approved the final version of the manuscript.
We thank M Gagnon and V Plante (Communicable Disease team Direction de la santé publique de l'Estrie) for their support with data collection and Dr. M Drapeau and Dr. S Perreault (Direction de la santé publique de l'Estrie) for contributing their clinical perspective during the investigation. We also thank Dr. M Kelly and S Michaud, two infectious disease physicians who treated the majority of patients in this case series.
This work was supported by the Public Health Agency of Canada, the Centre de recherche du CHUS and the Direction de la santé publique de l'Estrie.
Annex: Laboratory methods for detection of tick-borne infections
For Anaplasma phagocytophilum, the molecular detection is realized with an in-house real-time polymerase chain reaction (RT-PCR) targeting the msp2 gene. If positive, a conventional PCR and sequencing are performed to confirm and further characterize the strain of A. phagocytophilum Footnote 23. The National Microbiology Laboratory (NML) performed an indirect immunofluorescence assay (IFA) using the Focus A. phagocytophilum IFA IgG kit (DiaSorin Molecular, Cypress, California, United States), according to the manufacturer's instructionsFootnote 24.
For molecular detection of Babesia spp., amplification of the 18s rRNA gene common to all Babesia species is first performed. If positive, specific-species RT-PCR, melted-curve analysis, conventional PCR and sequencing are completed to establish speciesFootnote 25. Testing for antibody to Babesia microti was performed using a manual indirect immunofluorescent antibody (immunoglobulin G) assay (Imugen, Norwood, Massachusetts, United States)Footnote 26.
For Lyme disease, a first serological assay is performed at the Laboratoire de santé publique du Québec with a commercial enzyme immunoassay (ELISA Borrelia VlsE1/pepC10 IgG/IgM, Zeus Scientific, Branchburg, New Jersey, United States). If positive, the specimen is sent to the NML for confirmatory Western Blot (WB) for IgG antibodies against Borrelia burgdorferi (Anti-B. burgdorferi US EUROLINE IgG, Euroimmun, Lübeck, Germany). If the WB is negative, a Line Blot (LB) to detect IgM is executed (Anti-Borrelia EUROLINE-RN-AT-adv IgM, Euroimmun, Lübeck, Germany)Footnote 27.
This work is licensed under a Creative Commons Attribution 4.0 International License
Report a problem or mistake on this page
- Date modified: